Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD)

Paneez Khoury, Praveen Akuthota, Steven J. Ackerman, Joseph R. Arron, Bruce Scott Bochner, Margaret H. Collins, Jean Emmanuel Kahn, Patricia C. Fulkerson, Gerald J. Gleich, Rashmi Gopal-Srivastava, Elizabeth A. Jacobsen, Kristen M. Leiferman, Levi Schaffer Francesca, Sameer K. Mathur, Michael Minnicozzi, Calman Prussin, Marc E. Rothenberg, Florence Roufosse, Kathleen Sable, Dagmar Simon & 7 others Hans Uwe Simon, Lisa A. Spencer, Jonathan Steinfeld, Andrew J. Wardlaw, Michael E. Wechsler, Peter F. Weller, Amy D. Klion*

*Corresponding author for this work

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Eosinophil-associated diseases (EADs) are rare, heterogeneous disorders characterized by the presence of eosinophils in tissues and/or peripheral blood resulting in immunopathology. The heterogeneity of tissue involvement, lack of sufficient animal models, technical challenges in working with eosinophils, and lack of standardized histopathologic approaches have hampered progress in basic research. Additionally, clinical trials and drug development for rare EADs are limited by the lack of primary and surrogate endpoints, biomarkers, and validated patient-reported outcomes. Researchers with expertise in eosinophil biology and eosinophil-related diseases reviewed the state of current eosinophil research, resources, progress, and unmet needs in the field since the 2012 meeting of the NIH Taskforce on the Research of Eosinophil-Associated Diseases (TREAD). RE-TREAD focused on gaps in basic science, translational, and clinical research on eosinophils and eosinophil-related pathogenesis. Improved recapitulation of human eosinophil biology and pathogenesis in murine models was felt to be of importance. Characterization of eosinophil phenotypes, the role of eosinophil subsets in tissues, identification of biomarkers of eosinophil activation and tissue load, and a better understanding of the role of eosinophils in human disease were prioritized. Finally, an unmet need for tools for use in clinical trials was emphasized. Histopathologic scoring, patient- and clinician-reported outcomes, and appropriate coding were deemed of paramount importance for research collaborations, drug development, and approval by regulatory agencies. Further exploration of the eosinophil genome, epigenome, and proteome was also encouraged. Although progress has been made since 2012, unmet needs in eosinophil research remain a priority.

Original languageEnglish (US)
Pages (from-to)69-83
Number of pages15
JournalJournal of Leukocyte Biology
Volume104
Issue number1
DOIs
StatePublished - Jul 1 2018

Fingerprint

Eosinophils
Research
Biomarkers
Clinical Trials
Drug Approval
Translational Medical Research
Proteome
Rare Diseases

Keywords

  • biomarkers
  • eosinophil-related disorders
  • eosinophilia
  • hypereosinophilic syndromes
  • murine models
  • translational research

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Cell Biology

Cite this

Khoury, Paneez ; Akuthota, Praveen ; Ackerman, Steven J. ; Arron, Joseph R. ; Bochner, Bruce Scott ; Collins, Margaret H. ; Kahn, Jean Emmanuel ; Fulkerson, Patricia C. ; Gleich, Gerald J. ; Gopal-Srivastava, Rashmi ; Jacobsen, Elizabeth A. ; Leiferman, Kristen M. ; Francesca, Levi Schaffer ; Mathur, Sameer K. ; Minnicozzi, Michael ; Prussin, Calman ; Rothenberg, Marc E. ; Roufosse, Florence ; Sable, Kathleen ; Simon, Dagmar ; Simon, Hans Uwe ; Spencer, Lisa A. ; Steinfeld, Jonathan ; Wardlaw, Andrew J. ; Wechsler, Michael E. ; Weller, Peter F. ; Klion, Amy D. / Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD). In: Journal of Leukocyte Biology. 2018 ; Vol. 104, No. 1. pp. 69-83.
@article{f4bc092b6c9e4ddeb4d5b31fc9bcd297,
title = "Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD)",
abstract = "Eosinophil-associated diseases (EADs) are rare, heterogeneous disorders characterized by the presence of eosinophils in tissues and/or peripheral blood resulting in immunopathology. The heterogeneity of tissue involvement, lack of sufficient animal models, technical challenges in working with eosinophils, and lack of standardized histopathologic approaches have hampered progress in basic research. Additionally, clinical trials and drug development for rare EADs are limited by the lack of primary and surrogate endpoints, biomarkers, and validated patient-reported outcomes. Researchers with expertise in eosinophil biology and eosinophil-related diseases reviewed the state of current eosinophil research, resources, progress, and unmet needs in the field since the 2012 meeting of the NIH Taskforce on the Research of Eosinophil-Associated Diseases (TREAD). RE-TREAD focused on gaps in basic science, translational, and clinical research on eosinophils and eosinophil-related pathogenesis. Improved recapitulation of human eosinophil biology and pathogenesis in murine models was felt to be of importance. Characterization of eosinophil phenotypes, the role of eosinophil subsets in tissues, identification of biomarkers of eosinophil activation and tissue load, and a better understanding of the role of eosinophils in human disease were prioritized. Finally, an unmet need for tools for use in clinical trials was emphasized. Histopathologic scoring, patient- and clinician-reported outcomes, and appropriate coding were deemed of paramount importance for research collaborations, drug development, and approval by regulatory agencies. Further exploration of the eosinophil genome, epigenome, and proteome was also encouraged. Although progress has been made since 2012, unmet needs in eosinophil research remain a priority.",
keywords = "biomarkers, eosinophil-related disorders, eosinophilia, hypereosinophilic syndromes, murine models, translational research",
author = "Paneez Khoury and Praveen Akuthota and Ackerman, {Steven J.} and Arron, {Joseph R.} and Bochner, {Bruce Scott} and Collins, {Margaret H.} and Kahn, {Jean Emmanuel} and Fulkerson, {Patricia C.} and Gleich, {Gerald J.} and Rashmi Gopal-Srivastava and Jacobsen, {Elizabeth A.} and Leiferman, {Kristen M.} and Francesca, {Levi Schaffer} and Mathur, {Sameer K.} and Michael Minnicozzi and Calman Prussin and Rothenberg, {Marc E.} and Florence Roufosse and Kathleen Sable and Dagmar Simon and Simon, {Hans Uwe} and Spencer, {Lisa A.} and Jonathan Steinfeld and Wardlaw, {Andrew J.} and Wechsler, {Michael E.} and Weller, {Peter F.} and Klion, {Amy D.}",
year = "2018",
month = "7",
day = "1",
doi = "10.1002/JLB.5MR0118-028R",
language = "English (US)",
volume = "104",
pages = "69--83",
journal = "Journal of Leukocyte Biology",
issn = "0741-5400",
publisher = "FASEB",
number = "1",

}

Khoury, P, Akuthota, P, Ackerman, SJ, Arron, JR, Bochner, BS, Collins, MH, Kahn, JE, Fulkerson, PC, Gleich, GJ, Gopal-Srivastava, R, Jacobsen, EA, Leiferman, KM, Francesca, LS, Mathur, SK, Minnicozzi, M, Prussin, C, Rothenberg, ME, Roufosse, F, Sable, K, Simon, D, Simon, HU, Spencer, LA, Steinfeld, J, Wardlaw, AJ, Wechsler, ME, Weller, PF & Klion, AD 2018, 'Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD)', Journal of Leukocyte Biology, vol. 104, no. 1, pp. 69-83. https://doi.org/10.1002/JLB.5MR0118-028R

Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD). / Khoury, Paneez; Akuthota, Praveen; Ackerman, Steven J.; Arron, Joseph R.; Bochner, Bruce Scott; Collins, Margaret H.; Kahn, Jean Emmanuel; Fulkerson, Patricia C.; Gleich, Gerald J.; Gopal-Srivastava, Rashmi; Jacobsen, Elizabeth A.; Leiferman, Kristen M.; Francesca, Levi Schaffer; Mathur, Sameer K.; Minnicozzi, Michael; Prussin, Calman; Rothenberg, Marc E.; Roufosse, Florence; Sable, Kathleen; Simon, Dagmar; Simon, Hans Uwe; Spencer, Lisa A.; Steinfeld, Jonathan; Wardlaw, Andrew J.; Wechsler, Michael E.; Weller, Peter F.; Klion, Amy D.

In: Journal of Leukocyte Biology, Vol. 104, No. 1, 01.07.2018, p. 69-83.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD)

AU - Khoury, Paneez

AU - Akuthota, Praveen

AU - Ackerman, Steven J.

AU - Arron, Joseph R.

AU - Bochner, Bruce Scott

AU - Collins, Margaret H.

AU - Kahn, Jean Emmanuel

AU - Fulkerson, Patricia C.

AU - Gleich, Gerald J.

AU - Gopal-Srivastava, Rashmi

AU - Jacobsen, Elizabeth A.

AU - Leiferman, Kristen M.

AU - Francesca, Levi Schaffer

AU - Mathur, Sameer K.

AU - Minnicozzi, Michael

AU - Prussin, Calman

AU - Rothenberg, Marc E.

AU - Roufosse, Florence

AU - Sable, Kathleen

AU - Simon, Dagmar

AU - Simon, Hans Uwe

AU - Spencer, Lisa A.

AU - Steinfeld, Jonathan

AU - Wardlaw, Andrew J.

AU - Wechsler, Michael E.

AU - Weller, Peter F.

AU - Klion, Amy D.

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Eosinophil-associated diseases (EADs) are rare, heterogeneous disorders characterized by the presence of eosinophils in tissues and/or peripheral blood resulting in immunopathology. The heterogeneity of tissue involvement, lack of sufficient animal models, technical challenges in working with eosinophils, and lack of standardized histopathologic approaches have hampered progress in basic research. Additionally, clinical trials and drug development for rare EADs are limited by the lack of primary and surrogate endpoints, biomarkers, and validated patient-reported outcomes. Researchers with expertise in eosinophil biology and eosinophil-related diseases reviewed the state of current eosinophil research, resources, progress, and unmet needs in the field since the 2012 meeting of the NIH Taskforce on the Research of Eosinophil-Associated Diseases (TREAD). RE-TREAD focused on gaps in basic science, translational, and clinical research on eosinophils and eosinophil-related pathogenesis. Improved recapitulation of human eosinophil biology and pathogenesis in murine models was felt to be of importance. Characterization of eosinophil phenotypes, the role of eosinophil subsets in tissues, identification of biomarkers of eosinophil activation and tissue load, and a better understanding of the role of eosinophils in human disease were prioritized. Finally, an unmet need for tools for use in clinical trials was emphasized. Histopathologic scoring, patient- and clinician-reported outcomes, and appropriate coding were deemed of paramount importance for research collaborations, drug development, and approval by regulatory agencies. Further exploration of the eosinophil genome, epigenome, and proteome was also encouraged. Although progress has been made since 2012, unmet needs in eosinophil research remain a priority.

AB - Eosinophil-associated diseases (EADs) are rare, heterogeneous disorders characterized by the presence of eosinophils in tissues and/or peripheral blood resulting in immunopathology. The heterogeneity of tissue involvement, lack of sufficient animal models, technical challenges in working with eosinophils, and lack of standardized histopathologic approaches have hampered progress in basic research. Additionally, clinical trials and drug development for rare EADs are limited by the lack of primary and surrogate endpoints, biomarkers, and validated patient-reported outcomes. Researchers with expertise in eosinophil biology and eosinophil-related diseases reviewed the state of current eosinophil research, resources, progress, and unmet needs in the field since the 2012 meeting of the NIH Taskforce on the Research of Eosinophil-Associated Diseases (TREAD). RE-TREAD focused on gaps in basic science, translational, and clinical research on eosinophils and eosinophil-related pathogenesis. Improved recapitulation of human eosinophil biology and pathogenesis in murine models was felt to be of importance. Characterization of eosinophil phenotypes, the role of eosinophil subsets in tissues, identification of biomarkers of eosinophil activation and tissue load, and a better understanding of the role of eosinophils in human disease were prioritized. Finally, an unmet need for tools for use in clinical trials was emphasized. Histopathologic scoring, patient- and clinician-reported outcomes, and appropriate coding were deemed of paramount importance for research collaborations, drug development, and approval by regulatory agencies. Further exploration of the eosinophil genome, epigenome, and proteome was also encouraged. Although progress has been made since 2012, unmet needs in eosinophil research remain a priority.

KW - biomarkers

KW - eosinophil-related disorders

KW - eosinophilia

KW - hypereosinophilic syndromes

KW - murine models

KW - translational research

UR - http://www.scopus.com/inward/record.url?scp=85048806358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048806358&partnerID=8YFLogxK

U2 - 10.1002/JLB.5MR0118-028R

DO - 10.1002/JLB.5MR0118-028R

M3 - Review article

VL - 104

SP - 69

EP - 83

JO - Journal of Leukocyte Biology

JF - Journal of Leukocyte Biology

SN - 0741-5400

IS - 1

ER -